IMPLANTABLE PUMP FOR PROTEIN DELIVERY FOR OBESITY CONTROL BY DRUG INFUSION INTO THE BRAIN

• US 20100183700A1
• Filed: 02/22/2010
• Published: 07/22/2010
• Est. Priority Date: 10/07/2005
• Status: Active Grant

• Current Assignee: Codman & Shurtleff Incorporated (Johnson & Johnson)
• Original Assignee: Codman & Shurtleff Incorporated (Johnson & Johnson)
• Inventors: Stojanovic-Susulic, Vedrana, Cunningham, Mark, Venugopalan, Ramakrishna
• Granted Patent: US 8,252,744 B2
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 38/34 Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
• CPC Class Codes: A61K 47/6811 the drug being a protein or peptide, e.g. transferrin or bleomycin
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite.

Claims

1-17. -17. (canceled)

18. A system for suppressing appetite comprising:

an implantable drug infusion pump; and

a stable suspension of an effective dosage of an appetite suppressing agent

wherein the appetite suppressing agent can bind to a target receptor on a neural cell in the central nervous system and upon binding modifies the receptor function to suppress appetite.

19. The system of claim 18, wherein the appetite suppressing agent is a melanocyte-stimulating hormone (MSH).

20. The system of claim 19, wherein the melanocyte-stimulating hormone is alpha melanocyte-stimulating hormone (α

-MSH) peptide.

21. The system of claim 18, wherein the alpha melanocyte-stimulating hormone (α

-MSH) peptide is conjugated to an antibody or antibody fragment.